Cytokine Release Evaluation Service for Veterinary (Pet) Antibody

Creative Biolabs' cytokine release evaluation service for veterinary therapeutic antibody development is designed to de-risk your biologics and ensure preclinical safety. Are you facing the challenge of predicting and mitigating immune-related adverse events for your novel pet therapeutic antibodies? Our cytokine release evaluation service helps you accurately assess the risk of cytokine release syndrome (CRS) and other infusion reactions early in development. Through our robust in vitro whole blood and peripheral blood mononuclear cell (PBMC) assays, we provide critical safety data to guide lead candidate selection and ensure a smoother path to clinical trials.

Introduction

CRS is a systemic inflammatory response triggered by the activation of immune cells, leading to a massive release of cytokines like TNF-alpha and IL-6. In veterinary medicine, novel biologics such as therapeutic antibodies can inadvertently trigger CRS, posing a significant safety risk. In vitro cytokine release assays using whole blood or PBMCs from the target species are a critical preclinical tool. Our service provides a definitive preclinical assessment of the potential for your therapeutic antibody candidate to induce cytokine release in target veterinary species. We deliver a comprehensive data package that characterizes the pro-inflammatory profile, quantifies the magnitude of the cytokine response, and provides essential insights to de-risk your development program. By identifying potential liabilities early, we empower you to select the safest and most effective candidates, saving valuable time and resources.

Discover How We Can Help - Request a Consultation

Anti-IL-31RA pAbs Cytokine Assay Evaluation. (Li, et al., 2023) (OA Literature) Fig 1. Anti-IL-31RA pAbs decreased inflammatory cytokine and Th2 cytokine levels in the skin.^1,2

Workflow

Our cytokine release evaluation service is designed to assess the immunostimulatory potential of veterinary therapeutic antibodies by quantifying cytokine secretion from immune cells. This critical assay supports early safety profiling and species-specific immune risk assessment in dogs, cats, and other veterinary-relevant species.

Fig 2. Pet Antibody Cytokine Release Assay Evaluation Service Workflow. (Creative Biolabs Original)

Project Consultation & Experimental Planning	We begin with a detailed consultation to understand your antibody format, species specificity, and intended mechanism of action. Based on this, we design a tailored cytokine release assay using appropriate immune cells and readouts for canine, feline, equine, or bovine models.
PBMC or Whole Blood Preparation	We isolate peripheral blood mononuclear cells (PBMCs) or use fresh whole blood from healthy veterinary donors. Donor selection is documented and can be species- and breed-specific to reflect your target population.
Antibody Exposure & Incubation	Immune cells are incubated with your therapeutic antibody at multiple concentrations to mimic clinical exposure. Control groups include known stimulators and isotype controls to benchmark the cytokine response.
Cytokine Quantification	Following incubation (typically 6–48 hours), we measure cytokines in the supernatant using species-validated ELISA, multiplex bead-based assays, or electrochemiluminescence platforms. Key cytokines include IL-2, IFN-γ, TNF-α, IL-6, IL-10, and IL-1β, depending on the species and study goals.
Data Analysis & Reporting	We provide a comprehensive report including cytokine profiles, dose-response curves, statistical comparisons, and expert interpretation of cytokine release magnitude and risk. This helps you assess potential immunotoxicity and guide candidate selection.

Why Choose Us?

Veterinary-Specific Immune Assays
Our assays are optimized for canine, feline, equine, and bovine species using validated reagents and protocols. This ensures species-relevant immune response data that supports safe and effective therapeutic development.
Comprehensive Cytokine Profiling
We offer single and multiplex cytokine detection platforms (ELISA and MSD) tailored to your study goals. Quantify key proinflammatory and regulatory cytokines such as IL-2, IFN-γ, TNF-α, IL-6, and IL-10 with high sensitivity and accuracy.
Flexible Cell Sources
Choose from whole blood or PBMC-based assays with options for custom donor selection (breed, age, health status). This flexibility allows more realistic simulation of in vivo immune responses in target species.

FAQs

1. How sensitive is the assay? Can it detect low-level cytokine responses?

Our assays are highly sensitive, utilizing multiplex technology that can detect cytokine concentrations in the picogram per milliliter (pg/mL) range. This allows us to identify even subtle pro-inflammatory signals, providing a comprehensive risk profile for your therapeutic candidate.

2. My antibody has a novel mechanism of action. Can you customize the cytokine panel?

Absolutely. We understand that different biologics can trigger unique immune pathways. We offer standard inflammation-focused panels but can work with you to design a custom cytokine panel tailored to your antibody's specific target and expected mechanism. Let's discuss the possibilities.

Related Services

To further support your veterinary therapeutic development, Creative Biolabs offers a suite of complementary services.

T Cell Activation Evaluation

Assess the potential of your therapeutic to directly activate T cells, a key initiating event in some cytokine release syndromes.

Partner with Creative Biolabs

Creative Biolabs is dedicated to advancing the field of veterinary medicine by providing best-in-class preclinical research services. Our cytokine release evaluation service offers the critical safety data you need to make informed decisions, mitigate risk, and accelerate the development of your next innovative pet therapeutic.

Ready to ensure the safety profile of your therapeutic antibody? Our team of experts is here to help you design the optimal study for your project. Contact our team to learn more about our customized solutions for your pet therapeutic antibody cytokine release assays.

Contact Our Team for More Information and to Discuss Your Project.

References

1. Li, Qiuhua, et al. "Preparation of anti-canine interleukin-31 receptor alpha polyclonal antibody and evaluation of its therapeutic effect in canine atopic dermatitis." Animal Diseases 3.1 (2023): 26, https://doi.org/10.1186/s44149-023-00090-y
Distributed under Open Access license CC BY 4.0, without modification.

Services